Abstract
To explore the expression profile and prognostic relevance of GLUT-1 in pancreatic cancer, a meta-analysis, bioinformatics analysis based on Gene Expression Omnibus (GEO), Oncomine dataset and The Cancer Genome Atlas (TCGA) database, and immunohistochemistry in tumor and normal tissue from 88 pancreatic ductal adenocarcinoma (PDAC) patients were performed. GLUT-1 was significantly overexpressed in pancreatic cancer but it could not be a significant biomarker for prognosis. TNM stage and pathological grade could be biomarker of poor prognosis of patients with pancreatic cancer.
Ethical approval
The study was approved by the Medical Research Ethics Review Committee of Fudan University Huashan Hospital (Shanghai, China) (Review number: 2021-087). Informed consent was obtained for the use of patient tissues and medical histories in this study.
Declaration of interest
The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the article.
Data availability statement
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Correction Statement
This article has been republished with minor changes. These changes do not impact the academic content of the article.